What are the indications, dosing regimen, contraindications, and common adverse effects of ipratropium bromide?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ipratropium Bromide: Clinical Overview

Indications

Ipratropium bromide is indicated for maintenance treatment of bronchospasm in COPD and as adjunctive therapy in acute asthma exacerbations. 1

Primary Uses:

  • COPD maintenance therapy: Bronchodilation in stable chronic obstructive pulmonary disease
  • Acute asthma exacerbations: Added to short-acting beta-agonists (SABA) for severe exacerbations in the emergency department setting 2
  • Rhinorrhea: Intranasal formulation for common cold and allergic rhinitis (separate indication)

Important caveat: In asthma exacerbations, ipratropium should NOT be used as first-line monotherapy—it must be added to SABA therapy. Once a patient is hospitalized for asthma, adding ipratropium provides no further benefit 2.

For COPD, long-acting bronchodilators (LABAs or LAMAs like tiotropium) are preferred over ipratropium for maintenance therapy in moderate to severe disease, as they provide superior exacerbation prevention, quality of life, and lung function 3, 4.


Dosing Regimen

Inhaled Formulations (Bronchodilation):

COPD Maintenance (Adults):

  • Standard dose: 500 mcg (via nebulizer) three times daily 1
  • MDI: 42 mcg (2 puffs) four times daily 5

Acute Asthma Exacerbations:

  • Adults: 0.5 mg via nebulizer every 20 minutes for 3 doses, then as needed 2
  • Children: 0.25-0.5 mg via nebulizer every 20 minutes for 3 doses, then as needed 2
  • MDI (adults): 8 puffs every 20 minutes as needed up to 3 hours 2
  • MDI (children): 4-8 puffs every 20 minutes as needed up to 3 hours 2

Combination therapy: May be mixed in the same nebulizer with albuterol for convenience 2.

Intranasal Formulations (Rhinorrhea):

  • Common cold (adults): 84 mcg per nostril 3-4 times daily 6
  • Allergic rhinitis: 42-84 mcg per nostril 3 times daily 7
  • Children (2-5 years): 42-84 mcg per nostril 3 times daily 8

Contraindications

Absolute contraindications:

  • Hypersensitivity to ipratropium bromide, atropine, or its derivatives
  • Hypersensitivity to soya lecithin or related food products (peanut/soy allergy—applies to certain formulations)

Relative contraindications/Use with extreme caution:

  • Narrow-angle glaucoma: Cases of precipitation or worsening have been reported 1
  • Prostatic hyperplasia or bladder neck obstruction: Risk of urinary retention 1
  • Paradoxical bronchospasm: Discontinue immediately if this occurs

Critical warning: Avoid nebulizer mask contact with eyes—can precipitate acute angle-closure glaucoma and eye pain 1.


Common Adverse Effects

Respiratory (Most Common):

  • Bronchitis: 14.6-24.5% 1
  • Dyspnea: 9.6-16.7% 1
  • Cough: 4.6-8.0% 1
  • Bronchospasm: 2.3-5.4% (paradoxical) 1

Local Effects:

  • Dry mouth: 3.2% (increases with doses ≥2000 mcg/day) 1
  • Nasal dryness and epistaxis: Common with intranasal use 7, 6
  • Blood-tinged mucus: Well-tolerated and self-limiting 6

Systemic:

  • Headache: 6.4-9.0% 1
  • Dizziness: 2.3-4.0% 1
  • Hypertension: 0.9-4.0% 1

Serious but Rare:

  • Urinary retention 1
  • Acute angle-closure glaucoma and eye pain 1
  • Anaphylactic reactions, angioedema, urticaria, laryngospasm: Particularly in patients with drug/food allergy history 1
  • Tachycardia and palpitations 1

Reassuring safety data: Ipratropium does not impair mucociliary clearance or cause clinically significant increases in mucus viscosity 9. Serious adverse events are significantly less common than with some alternatives (OR 0.5 vs ipratropium in one comparison) 4.


Key Clinical Pearls

Dosing threshold for side effects: Headache, dry mouth, and COPD symptom aggravation become more common when total daily dose equals or exceeds 2000 mcg 1.

Combination therapy advantage: Adding ipratropium to SABA in acute asthma provides additional bronchodilation with no significant increase in serious adverse events 3, 2.

Duration of benefit in acute settings: In emergency department management of asthma, ipratropium has been studied for up to 3 hours of repeated dosing 2.

Intranasal use: The 0.06% nasal spray formulation is safe and effective even in children as young as 2 years, with minimal systemic anticholinergic effects 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.